A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation

Liver Transplantation

Volumn 13, Issue 7, 2007, Pages 975-983

  Yilmaz, Nevin ^a   Shiffman, Mitchell L ^a   Stravitz, R Todd ^a   Sterling, Richard K ^a   Luketic, Vellmir A ^a   Sanyal, Arun J ^a   Mills, A Scott ^a   Contos, Melissa J ^a   Coterell, Adrian ^a   Maluf, Daniel ^a   Posner, Marc P ^a   Fisher, Robert A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAUSE OF DEATH; CHRONIC DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ETHNICITY; FATALITY; FATTY LIVER; FEMALE; FOLLOW UP; GRAFT FAILURE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT INFECTION; SEPSIS;

ADULT; ANTIVIRAL AGENTS; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; RNA, VIRAL; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 34547455714     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21117     Document Type: Article

References (38)

1. Shiffman ML, Saab S, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, Schaubel DE. Liver and intestine transplantation in the United States, 1995-2004. Am J Transplant 2006;6:1170-1187.
2. Charlton M, Wiesner R. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 2004;24(Suppl 2):79-88.
3. Biggins SW, Terrault NA. Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis 2005;9:505-523.
4. Brown RS Jr. Hepatitis C and liver transplantation. Nature 2005;436:973-978.
5. Forman LM, Lewis JD, Berlin LA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896,
6. Gane EJ, Portmann BJ, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
7. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-256.
8. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-858.
9. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003;76:1487-1491.
10. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
11. Shiffman ML, Vargus HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003;9:1129-1144.
12. Gretch D, Corey L, Wilson J, de la Rosa C, Willson R, Carithers R Jr, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994;169:1219-1225.
13. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmarm BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
14. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
15. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-722.
16. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004:10:859-867.
17. Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10:850-858.
18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
19. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
20. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
21. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
22. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130:1636-1642.
23. Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006;43:780-787.
24. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy pan stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-1247.
25. Sebagh M, Rifai K, Feray C, Yi1maz F, Falissard B, Roche B, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003;37:1293-1301.
26. Feray C. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41: 862-863.
27. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-262.
28. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.
29. Condron SL, Heneghan MA, Patel K, Dev A, McHutchison JG, Muir AJ. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation 2005;80:145-148.
30. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006;81:7-14.
31. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
32. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005;241:905-916.
33. Cuende N, Miranda B, Canon JF, Garrido G, Matesanz R. Donor characteristics associated with liver graft survival. Transplantation 2005;79:1445-1452.
34. Rifai K, Sebagh M, Karam V, Saliba F, Azoulay D, Adam R, et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004,41:446-453.
35. Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996;61:402-406.
36. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006;43:492-429.
37. Kimball P, Verbeke S, Shiffiman M. HCV core protein augments cyclosporine immunosuppression. Transplant Proc 2005;37:652-653.
38. Yao ZQ, Ray S, Eisen-Vandervelde A, Waggoner S, Hahn YS. Hepatitis C virus: immunosuppression by complement regulatory pathway. Viral Immunol 2001;14:277-295.